John Bucksath, MBA
Mr. Bucksath joined ABC Laboratories as an analytical chemist in 1989. He was responsible for the successful start-up, growth and leadership of the company’s pharmaceutical CGMP Analytical Services group in the mid-1990s. John was promoted to VP of company operations in 2003 where he managed all operations of the organization’s pharmaceutical and agri-chemical business and was responsible for the company’s P/L. John was promoted to Sr. Vice President of Operations in 2005 and in 2007 initiated the Company’s program management function and Quality Management metric program. In 2008, John was named Senior Vice President and General Manager of the company’s Pharmaceutical Division where he was responsible for all aspects of the operations including business development. John developed and initiated the company’s intro into large molecule product development services. In September 2012, John was selected as President and CEO/Board member of ABC and Morse Laboratories. Under John’s leadership the Company grew at a CAGR of > 15% annually and in 2015, ABC Laboratories was successfully sold to the Evans Analytical Group (EAG).
John joined Kansas City Analytical Services (KCAS) as CEO/Board member in 2016. John serves on the Missouri Biotechnology Association’s Board of Directors as Treasurer and is a member of the University of Missouri’s Research and Development Advisory Board and is a member of the University of Missouri’s Venture Mentorship team focused on early startup life science companies. John has also served as an observing Board Member for two early-mid stage biotechnology companies.
John’s undergraduate education in Biology and Chemistry was obtained from Central Methodist University and a Masters of Business Administration from the Olin Business School – Washington University in St. Louis.
Michael Lanman is Vice President of Operations at KCAS. Since joining the company in 1982, Michael has worked in and managed essentially every department within the company’s operations. A major emphasis in his business philosophy is focusing on customer communications and service. His responsibilities include overseeing day-to-day operations, managing budgets and contracts, IT support and ensuring the facilities are running smoothly. Michael leverages his extensive bioanalytical operational experience to ensure customer satisfaction and on-time projects. Michael holds a BA in Education from Bethany College in Lindsborg, KS.
Dr. Amy Mize began her career at ABC Laboratories in 2002. She started as a bioanalytical chemist in the large molecule laboratory. In 2005 Amy was responsible for laboratory operations, as the Director of the preclinical service offering (DMPK, Bioanalysis and Synthesis services). During this time, the operation made significant progress in process improvement and client satisfaction. Amy transitioned to Business Development in 2010. During this time, Amy helped build systems in sales and operations planning, to help forecast the business and improve planning. In 2012, Amy was promoted to Vice President, Business Development at which time she took on responsibility for the Sales pipeline for the pharmaceutical and Agri-Chemical businesses. Amy was instrumental in helping the company grow at a CAGR of >15% annually. In 2015, ABC laboratories was successfully sold to Evans Analytical Group (EAG), and Amy was a member of the Senior Leadership team during this transition.
In 2015, Amy was promoted to Vice President, Business Development and Commercial Operations for EAG Laboratories. In this role, Amy was responsible for the Sales and Operations Planning function and overall Sales for the Pharmaceutical and Agri-Chemical Service offerings. In addition, integration and process improvement were key functions Amy helped to support, bringing multiple sites and brands together as one. In 2017, EAG was successfully sold to Eurofins.
In 2018, Amy joined KCAS as Vice President, Business Development. Amy brings experience in capacity planning, operational management, and a track record of building superior sales and marketing teams capable of serving the needs of the pharmaceutical industry.
Amy’s undergraduate education in Chemistry was obtained from Baker University (Baldwin City, KS), and Ph.D. in Pharmacology from the University of Kansas (Medical Center Campus).
Maria Nelson is the Senior Director of Finance and Administration at KCAS. Maria joined KCAS in 2015, and leads the teams that provide the finance, accounting, and human resource functions within the organization. Maria brought with her a diverse background of experience in managing multiple aspects of early-stage high-growth companies. Functioning in a highly operational capacity, her strengths lie in bringing together people and information across departments, and organizing teams in a way that allows data to best be utilized for quality decision making. Prior to joining KCAS, Maria served as an Executive in multiple industries within the technology and professional services sectors.
Maria holds a Bachelor’s of Science in Accounting and Business Administration from the University of Kansas.
Mr. Goodwin is the Executive Director of Bioanalytical R&D and LC-MS/MS Services at KCAS Bioanalytical & Biomarker Services in Shawnee, Kansas. Business development, strategic planning, portfolio expansion, client-based solutions, and driving key scientific objectives for bioanalytical R&D and LC-MS/MS Services are among his primary responsibilities. Mr. Goodwin brings with him the breadth of knowledge to provide scientific and technical leadership across the drug development spectrum including Discovery, Safety Assessment, and Biologics Testing Solutions areas; he has been with KCAS since January 2018. Lawrence Goodwin has significant drug development aptitude within pharmaceutical and CRO industries. He has lead teams responsible for bioanalytical programs from Discovery through New Drug Application filings. He has more than 25 years’ experience in the Life Sciences industry which includes most recently Eli Lilly and Company and Charles River Laboratories. Leveraging tandem mass spectrometry, Lawrence has made significant contributions in the fields of Bioanalytical, Analytical, Safety Assessment, Biotherapeutics, and Integrated Drug Discovery. He has authored or co-authored more than 35 papers and presentations and provided over 150 internal documents.
Lawrence received his BS in Biological Chemistry from Fontbonne University, St. Louis, Missouri in 1986 and graduated Cum Laude. His continuing education includes the following areas: executive leadership, people and resource management, advanced instrumentation, and GLP training. He has been the recipient of numerous awards both as an individual contributor and as a leader, especially in the areas of tandem mass spectrometry, data management, and process/work-flow efficiency. He is the former chair of the Eli Lilly Mass Spectrometry group and is an active member of American Society for Mass Spectrometry, and a current member of executive leadership team at KCAS.
Mr. Franklin P. Spriggs received his B.S. in microbiology from Ohio University in 1998. Upon graduation he moved to New Haven, Connecticut to join CurGen Corp, a small biotechnology company working in the area of genomics and protein binding interactions. In 2005, Mr. Spriggs left New England and headed to southern California to join Amgen, Inc in Thousand Oaks. While at Amgen, Mr. Spriggs had the opportunity to learn and build expertise in regulated large molecule bioanalysis. Late 2007 saw Mr. Spriggs leave California and travel back to the northeast to join Pfizer, Inc in Groton Connecticut. While at Pfizer he applied the knowledge he had learned while at Amgen and began to participate in the American Association of Pharmaceutical Sciences (AAPS) where he has held positions in both the BIOTEC and Regulatory Sciences sections. In 2015 Mr. Spriggs received his M.S. in Regulatory Affairs and Quality Assurance from Temple University before transitioning out of the pharmaceutical industry to the world of the Contract Research Organization (CRO). Previous to KCAS, LLC Mr. Spriggs spent a 2 year tenure at another CRO in Indianapolis, IN, AIT Bioscience as the Ligand Binding Assay Group Leader.
Yansheng Liu, PhD
Dr. Yansheng Liu is a Senior Director with KCAS, managing the Bioanalytical Research and Development team and the LC-MS/MS laboratory. He joined KCAS in 1997 after completion of his post-doctoral research in analytical chemistry at Indiana University. He has developed and validated hundreds of bioanalytical methods with his team using LC-MS/MS combined with on-line and off-line sample cleanup techniques. He diligently monitors the performance of each validated method to ensure quality performance over time. Dr. Lui excels at troubleshooting instrument-method, and operation-related problems to ensure quality and timeline management. He continuously demonstrates his dedication to clients’ bioanalytical needs in drug discovery and development activities and uses his strength in solving challenging bioanalytical problems to meet regulatory requirements. He has also authored over 40 publications and presentations.
Gene Ray, PhD
Gene Ray, PhD, is a Senior Scientific Advisor, his role is to serve as scientific and technical advisor for both clients and internal teams for development, validation, and application of bioanalytical methods for small molecule therapeutics and alkaline hematin endpoint marker studies. Since joining the company in 1990, he has gained expertise is in a full range of bioanalytical techniques, including LC-MS/MS, GC/MS/MS, ELISA, RIA, protein binding and mass balance investigations. Gene has experience developing novel methods and acting as a Principal Bioanalytical Investigator for a vast number of client programs; analyzing hundreds of pharmaceutical compounds in blood, urine and various tissues. He previously served at Midwest Research Institute as the Assistant Director for numerous analytical chemistry programs for the National Cancer Institute.
Dominic Warrino, PhD
Dominic Warrino, PhD, is a Senior Scientific Advisor, his role is to serve as scientific and technical advisor for both clients and internal teams for development, validation, and application of bioanalytical, immunogenicity, and biomarker methods for large molecule therapeutics. Dominic joined the company in 2013, and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, Flow Cytometry, ELISpot, cell based assays and Luminex. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent several years in the Biopharma Services department at Viracor-IBT (formally IBT), and previously also worked for Cytogen (formally Cellcor), Eligix, and Streck Laboratories developing novel compounds for treatment of various cancers. Dominic has worked on over 100 large molecule compounds developing and validating PK, PD, ADA, and Biomarker assays in support of pre-clinical to phase IV testing.
Victor has 26 years of experience working in bioanalytical laboratories; 11 of those years in Quality Assurance (QA). He spent five years as a QA specialist and has spent the last six years in QA management. He has been a Registered Quality Assurance Professional in GLPs since 2002. Since joining KCAS in 2006, he has played an important role in client interactions regarding KCAS’ quality as well as implementing quality improvement in practices, procedures and training. As Director of Quality Assurance, Green has been involved in multiple FDA regulatory inspections and client audits. He supervises quality staff auditing activities for projects and clients, which involves resolving quality issues, notifying senior management of issues related to quality and providing status updates for GLP studies. Prior to joining KCAS, Green had 16 years experience as a chemist in bioanalytical laboratories for Marion Merrel Dow, Hoechst Marion Roussel and Quintiles.
Ms. Pamela Burnett received her B.S, from McGill University in Montreal, Canada in 1980. She has over 20 years of experience managing laboratories and studies focused on bioanalyis, pharmaceutical finished product analysis and toxicology study analytical support. She played a key role in the startup of a bioanalytical CRO, authoring the SOPs, instituting the GLP program, and overseeing IQ/OQ/PQ as well as software validation activities. In her 4 years since joining KCAS she has acted as Principal Bioanalytical Investigator on numerous studies and has been instrumental in improving quality and compliance in the laboratory.